**Venue**

_Ergife Palace Hotel and Congress Centre_
Via Aurelia, 619
00165 Rome, Italy

**Language**

English is the official language of the Congress. No simultaneous translation will be available.

**Continuing Medical Education**

The 5th EAHAD Congress has been recognized by EHA-CME Unit as CME event for Hematologists and will grant 9.5 credits to attending participants.

Accreditation for Italian Continuing Medical Education has also been obtained for the following specialties: haematology, medical genetics, internal medicine, pediatrics, orthopaedics, transfusion medicine, clinical pathology, biology, psychology, nursing sciences. The number of Italian CME credits granted to participants attending the whole Congress is 7.5.

**Liability**

The Congress Organizers cannot accept liability for personal injuries sustained or for loss or damage to property belonging to Congress Participants, either during or as a result of the Congress. Please check the validity of your insurance.
THE ASSOCIATION

The European Association for Haemophilia and Allied Disorders is a multi-disciplinary association of healthcare professionals who provide care for individuals with haemophilia and other bleeding disorders. EAHAD purpose is to promote clinical care, education and research for this group of patients across the continent. Visit the Association website at www.eahad.org.

EAHAD EXECUTIVE COMMITTEE

Pier Mannuccio Mannucci, President
Jan Astemarck, Vice-President
Philippe de Moerloose, Secretary
Christopher A. Ludlam, Treasurer
Gerry Dolan, Company Secretary
Kathelijn Fischer
Christine Harrington
Cedric Hermans
Johannes Oldenburg
Elena Santagostino
Jerzy Windyga
**WEDNESDAY, FEBRUARY 22ND**

**12.00-19.00**  
**REGISTRATION**

**14.30-16.00**  
**SATELLITE SYMPOSIUM – Factor VIII inhibitor: the most cogent unresolved issue in haemophilia**  
**GRIFOLS, KEDRION, LFB**  
**CHAIRS:** F. Peyvandi (Italy), J. Goudemand (France)  
**Risk factors for inhibitors: can they be controlled?**  
- In previously untreated patients  
  E. Santagostino (Italy)  
- In previously treated patients  
  C. Hay (UK)

**Immune tolerance induction: the optimal choice of factor VIII product**  
**C. Escuriola Ettingshausen (Germany)**

**16.00-16.30** **BREAK**

**16.30-18.00**  
**SATELLITE SYMPOSIUM – Managing haemophilia for life: Thoughts on safety and efficacy**  
**PFIZER**  
**CHAIRS:** P.M. Mannucci (Italy), M. Makris (UK)  
**Welcome and introduction**  
Co-Chairmen  
**Inhibitor development: how to assess the risk**  
**J. Astephan (Sweden)**  
**Monitoring safety and efficacy over the long-term: the role of registries**  
**K. Fischer (the Netherlands)**  
**The science of switching**  
**C. Hay (UK)**  
**Optimal prophylaxis in haemophilia B: new developments**  
**L. Valentino (USA)**  
**Q&A**  
**Facilitated by Co-Chairmen**  
**Summary**  
Co-Chairmen

**18.00-19.30**  
**SATELLITE SYMPOSIUM – Haemophilia with inhibitors: current state and future options**  
**NOVO NORDISK**  
**CHAIRS:** M.G. Mazzucconi (Italy), P.M. Mannucci (Italy)  
**Introduction**  
A. Obergfell (Novo Nordisk, Switzerland)  
**Early treatment means rapid bleeding control**  
**M. Morfini (Italy)**  
**The importance of treatment optimization in children**  
**E. Santagostino (Italy)**  
**Current management of ITI**  
**M.E. Mancuso (Italy)**  
**Future of haemostasis in inhibitor patients: beyond current treatment**  
**S.E. Bjørn (Novo Nordisk, Denmark)**  
**Discussion and conclusions**

**19.30**  
**EAHAD EXECUTIVE COMMITTEE MEETING**

**THURSDAY, FEBRUARY 23RD**

**8.00-9.30**  
**SATELLITE SYMPOSIUM – A natural pathway to longer lasting haemophilia therapies**  
**SWEDISH ORPHAN BIOVITRUM AND BIOGEN IDEC HEMOPHILIA**  
**CHAIRMAN AND CO-CHAIR:** J. Astephan (Sweden), S. James (Sweden)  
**A new age in haemophilia management**  
- Chairmen introduction  
- Extending treatment through life and disease  
  **M. Makris (UK)**
Fc fusion technology: a new approach for drug development in haemophilia

- Fc fusion technology
  P. Lind (Sweden)
- Assays – A technical overview
  J.M. Sommer (USA)

Longer lasting coagulation factors

- Clinical investigation of rFVIIIFc – a longer lasting coagulation factor VIII
  R. Klamroth (Germany)
- Individualized treatment - Coagulation factor pharmacokinetics and implications for treatment
  J. Pasi (UK)

Questions and panel discussion

09.30-10.30  SCIENTIFIC SESSION 1

CHAIRS: P.M. Mannucci (Italy), J. Andermark (Sweden)

The European Haemophilia Safety Surveillance System (EUHASS)
M. Makris (UK)

EAHAD working parties:

- IPD meta-analysis to investigate risk factors for inhibitor development
  A. Iorio (Italy)
- EAHAD working party on mutation databases
  C. Ludlam (UK)
- EAHAD working party on factor VIII assay discrepancies
  J. Oldenburg (Germany)
- EAHAD working party on epidemiology and management of rare bleeding disorders
  F. Peyvandi (Italy)

10.30-11.00  BREAK

11.00-12.00  SCIENTIFIC SESSION 2

CHAIRS: C.A. Ludlam (UK), J. Windyga (Poland)

New drugs for hepatitis C: their role in haemophilia and allied disorders
C. Colomba (Italy)

Outcome assessment in haemophilia therapy
V. Blanchette (Canada)

Ultrasound diagnosis of haemophilic arthropathy
C. Martinoi (Italy)

12.00-12.30  BREAK

12.30-14.00  LUNCH SATELLITE SYMPOSIUM - Prophylaxis for life?

BAYER HEALTHCARE

SESSION CHAIRS: J. Andermark (Sweden), M. Morfini (Italy)

Welcome
J. Andermark (Sweden)

Interactive case discussions:

- Personalized prophylaxis: a “good companion” for life
  C. Santoro (Italy)
- Obstacles to treatment: overcoming inhibitors in prophylaxis
  P.A. Holme (Norway)

Current clinical evidence
R. Klamroth (Germany)

Pharmacokinetics – are there differences between children and adults?
S. Björkman (Sweden)

Discussion and conclusion
J. Andermark (Sweden), M. Morfini (Italy)

14.00-14.30  BREAK

14.30-16.00
16.30-17.30  **Scientific Session 3**  
**Chairs:** C. Hermans (Belgium), M. Makris (UK)  
Prophylaxis in rare bleeding disorders  
P. de Moerloose (Switzerland)  
Factor XIII deficiency: diagnostic and therapeutic issues  
H. P. Kohler (Switzerland)  

17.30-18.30  **EAHAD General Assembly**  

20.00-22.00  **Congress Dinner**  

---

**Friday, February 24th**  

8.30-10.30  **Scientific Session 4**  
**Chairs:** K. Fischer (the Netherlands), G. Dolan (UK)  
Tranexamic acid: the haemostatic drug of choice  
M. Levi (the Netherlands)  
Global coagulation tests: their role in haemophilia and acquired coagulation disorders  
Y. Dargaud (France)  
The ITI Study: clinical implications  
C. Hay (UK)  
The use of the clinical trial design in haemophilia: methodological considerations  
A. Iorio (Italy)  

10.30-11.00  **Break**  

11.00-12.30  **Scientific Session 5**  
**Chairs:** W. Schramm (Germany), F. Peyvandi (Italy)  
EMA and FDA requirements for licensing new haemophilia products: do they truly provide answers on safety/efficacy?  
L. Aledort (USA), E. Santagostino (Italy), C. Male (Austria)  

12.30-12.45  **Break**  

---

12.45-14.15  **Lunch Session - Poster Viewing and Manning**  
**Coordinators:** J. Astemark (Sweden), E. Santagostino (Italy), J. Windyga (Poland)  

14.15-14.30  **Break**  

14.30-16.00  **Scientific Session 6**  
**Chairs:** J. Oldenburg (Germany), P. de Moerloose (Switzerland)  
VWF, angiodyplasia and endothelial progenitor cells: novel insights from basic science  
A.M. Randi (UK)  
The value of genotyping in predicting poor response to desmopressin in mild haemophilia and von Willebrand disease  
G. Castaman (Italy)  
Gene therapy trial in severe haemophilia B  
E. Tuddenham (UK)  

---

**Conclusions and CME Questionnaire (For Italian delegates only)**
Pfizer Haemophilia is dedicated to improving the lives of haemophilia patients

A world leader in advanced therapies for haemophilia

Devoted to treatments you can trust

Long-standing commitment to the haemophilia community
Announcement
3rd Arosenius Lecture

Edward Tuddenham, UK
Gene therapy trial in severe haemophilia B: interim results
Friday, 24th February - h 15:30

History of the Arosenius Fund

The Arosenius Fund was established in 1996 and is the research fund of the Swedish Haemophilia Society. The Board of the fund consists of representatives from the fields of gene therapy and haemophilia care as well as members of the Society. The fund is sponsored by unrestricted grants, and it is named after Sweden’s best loved artist Ivar Arosenius (1878–1909), who suffered from haemophilia and died at the young age of 31. He had a brother with haemophilia who died at the result of bleed at the age of 14. Ivar’s paintings reflect his disease and are a celebration of his way of life, expressing a mixture of humour and bitter sarcasm. His best-known work is the Cat Journey, which he drew for his daughter Lilian, and has become the symbol of the fund ‘Lilian and the Cat’.

The aim of the Fund

The aim and vision of the Arosenius Fund is to promote research for finding a cure for haemophilia. Therefore, the fund annually announces research grants currently set at 10 000 and 30 000 Euros, respectively, as well as travel grants to scientific congresses for scientists and professionals engaged in the field of haemophilia. The fund also supports symposia and lectures to reach the national and international research community. For many years an annual Arosenius lecture has been held during the WFH congress and, beginning 2010, a lecture is also given at the annual meeting of the European Association of Haemophilia and Allied Disorders (EAHAD). The first lecture at the EAHAD congress was given by P. M. Mannucci. In 2011, C. Rodriguez-Merchan was invited to give a lecture on haemophilic arthropathy. This year, the Arosenius lecture is given by E. Tuddenham on Friday 24th at 15:30. A review of his presentation is included in Volume 18, Supplement 1 of Haemophilia. The Arosenius Fund will, during the years to come, continue its commitment to support the field of haemophilia from the perspectives of the patient, the clinic and the scientific community to contribute to the improvement of treatment and knowledge of the disease world-wide.